Work

Responders to ELND005 (Scyllo-Inositol) Demonstrate Clinical and Biomarker Characteristics Consistent with Mild Alzheimer's Disease (AD): Data from a 78-Week Phase 2 Study in Mild to Moderate (M/M) AD (P04.194)

Year: 2012

Type: conference-abstract

Source: Neurology

DOI: 10.1212/wnl.78.1_meetingabstracts.p04.194

Authors: A. Porsteinsson, R. Sperling, S. Salloway, G. Crans, C. Hernandez, S. Abushakra

Institutions: University of Rochester Medicine, University of Rochester, Brigham and Women's Hospital, Harvard University, Brown University, Butler Hospital, Elan Pharmaceuticals, Inc. (Ireland)

Language: English

Topic: Alzheimer's disease research and treatments

Subfield: Physiology (medical)

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2001454508

Cites:

Cited by: 1

Related to: 10